APA (7th ed.) Citation

Shorr, A. F., Schranz, J., Goldberg, L., Paukner, S., Das, A. F., Moran, G. J., . . . Gelone, S. P. (2019). 663. Efficacy and Safety of Lefamulin (LEF) vs. Moxifloxacin (MOX) for Legionella pneumophila (LP) in Patients with Community-Acquired Bacterial Pneumonia (CABP): Pooled Results From the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Phase 3 Clinical Trials. Open Forum Infectious Diseases, 6, S303. https://doi.org/10.1093/ofid/ofz360.731

Chicago Style (17th ed.) Citation

Shorr, Andrew F., et al. "663. Efficacy and Safety of Lefamulin (LEF) Vs. Moxifloxacin (MOX) for Legionella Pneumophila (LP) in Patients with Community-Acquired Bacterial Pneumonia (CABP): Pooled Results From the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Phase 3 Clinical Trials." Open Forum Infectious Diseases 6 (2019): S303. https://doi.org/10.1093/ofid/ofz360.731.

MLA (9th ed.) Citation

Shorr, Andrew F., et al. "663. Efficacy and Safety of Lefamulin (LEF) Vs. Moxifloxacin (MOX) for Legionella Pneumophila (LP) in Patients with Community-Acquired Bacterial Pneumonia (CABP): Pooled Results From the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Phase 3 Clinical Trials." Open Forum Infectious Diseases, vol. 6, 2019, p. S303, https://doi.org/10.1093/ofid/ofz360.731.